Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution

详细信息    查看全文

• 作者：Zhenzhen Liu (1)
  Yukun Feng (1)
  Lunhui Zhang (1)
  Guofei Li (1)
  Lulu Geng (1)
  Yan Cui (1)
  Fei Teng (1)
  Xing Tang (1)
  Kaishun Bi (1)
  Xiaohui Chen (1)
  
• 关键词：UPLC ; MS/MS ; Larotaxel ; Lipid microsphere ; Pharmacokinetics ; Tissue distribution
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2013
• 出版时间：May 2013
• 年：2013
• 卷：71
• 期：5
• 页码：1131-1139
• 全文大小：571KB
• 参考文献：1. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665鈥?67 CrossRef
  2. Gueritte-Voegelein F, Guenard D, Lavelle F, LeGoff MT, Mangatal L, Potier P (1991) Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34:992鈥?98 CrossRef
  3. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW (1998) Microtuble changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48:4093鈥?100
  4. Gelmon KA, Latreille J, Tolcher A, Genier L, Fisher B, Forand D, D鈥橝loisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E (2000) PhaseIdose-finding study of a new taxane, RPR109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol 18:4098鈥?108
  5. Zatloukal P, Gervais R, Vansteenkiste J, Bosquee L, Sessa C, Brain E, Dansin E, Urban T, Dohollou N, Beenval M, Quoix E (2008) Phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol 3:894鈥?01 CrossRef
  6. Sabtos LE, Colhone MC, Daghastanli KR, Stabeli RG, Silva-Jardim L, Ciancaglini P (2009) Lipid microspheres loaded with antigenic membrane proteins of the / Leishmania amazonensis as a potential biotechnology application. J Colloid Intefe Sci 340:112鈥?18 CrossRef
  7. Muller RH, Schmidt S, Buttle I, Akkar A, Schmitt J, Bromer S (2004) Solemuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm 269:293鈥?02 CrossRef
  8. Zuylen LV, Verweij J, Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125鈥?41 CrossRef
  9. Windebank AJ, Blexrud MD, De Groen PC (1994) Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 268:1051鈥?056
  10. Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A (1999) Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 5:2918鈥?924
  11. Beijnen JH, Schellens M (2004) Drug interactions in oncology. Lancet Oncol 5:489鈥?96 CrossRef
  12. Engels FK, Mathot RAA, Verweij J (2007) Alternative drug formulation of docetaxel: a review. Anticancer Drugs 18:95鈥?03 CrossRef
  13. Santos LER, Colhone MC, Daghastanli KRP, Stabeli RG, Silva-Jardim I, Ciancaglini P (2009) Lipid microspheres loaded with antigenic membrane proteins of the / Leishmania amazonensis as a potential biotechnology application. J Colloid Interf Sci 340:112鈥?18 CrossRef
  14. Singh M, Ravin IJ (1986) Parenteral emulsions as drug carrier systems. J Parenter Sci Technol 40:34鈥?1
  15. Wang L, He H, Tang X, Shao R, Chen D (2006) A less irritant norcantharidin lipid microspheres: formulation and drug distribution. Int J Pharm 323:161鈥?67 CrossRef
  16. Floyd AG (1999) Top ten considerations in the development of parenteral emulsions. Phar Sci Tech Today 2:134鈥?43 CrossRef
  17. Liu ZZ, Zhang B, Liu ZH, Li S, Li G, Geng LL, Zhao X, Bi KS, Tang X, Chen X (2012) Development of a UPLC-ESI-MS/MS method for the determination of larotaxel in beagle dog plasma: application to the pharmacokinetic study. Anol Bioanal Chem 403:323鈥?30 CrossRef
  18. Sessa C, Cuvier C, Caldiera S, Bauer J, Vanden Bosch S, Monnerat C, Semiond D, Perard D, Lebecq A, Besenval M, Marty M (2002) PhaseIclinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administrated as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 13:1140鈥?150 CrossRef
  19. Yamamoto N, Boku N, Minami H (2009) Phase I study of larotaxel administered as a 1-h intravenous in fusion every 3聽weeks to Japanese patients with advanced solid tumours. Canc Chemother Pharmacol 65:129鈥?36 CrossRef
  20. Kurata T, Shimada Y, Tamura T, Yamamato N, Hyodo I, Saeki T, Takashima S, Fujiwara K, Wakasugi H, Kashimura M (2000) Phase I and pharmacokinetic study of a new taxoid RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol 18:3164鈥?171
  21. Fang LN, Chen XH, Wang QD, Zhang D, Zhao JJ, Long ZM, Gong P, Bi KS (2011) A liquid chromatography-tandem mass spectrometry method for the quantification of PAC-1 in rat plasma. J Pharm Biomed Anal 54:225鈥?29 CrossRef
  22. Di B, Feng N, Liu W (2006) Pharmacokinetic comparisons of Shuang-Huang-Lian with the different combinations of its constitutional herbs. J Ethnopharmacol 107:401鈥?05 CrossRef
  23. FCDER (Center for Drug Evaluation and Research) (2001) Guidance for Industry, Bioanalytical Method Validation, US FDA. lianceRegulatoryInformation/Guidances/UCM070107.pdf" class="a-plus-plus">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf
  24. Nallani SC, Goodwin B, Maglich JM, Buckley DJ, Buckley AR, Desai PB (2000) Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor. Drug Metab Dispos 28:360鈥?66
  25. Marre F, Sanderink G, Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296鈥?302
  26. Gibbs MA, Thummel KE, Shen DD, Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of k1 values and impact of CYP3A5 expression. Drug Metab Dispos 27:180鈥?87
  27. Newton DJ, Wang RW, Lu AH (1995) Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154鈥?58
  28. Tanaka E (1999) Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24:339鈥?46 CrossRef
  29. Waxman D, Dannan G, Guengerich F (1995) Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry 24:4409鈥?417 CrossRef
  30. Shi S, Chen H, Cui Y, Tang X (2009) Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion. Int J Pharm 373:147鈥?55 CrossRef
  31. Zhao M, Su M, Lin X, Luo Y, He H, Cai C, Tang X (2010) Evaluation of docetaxel-loaded intravenous lipid emulsion: pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Phrm Res 27:1687鈥?702 CrossRef
  32. Abra RM, Hunt CA, Lau DT (1984) Liposome disposition in vivo VI: delivery to the lung. J Pharm Sci 73:203鈥?06 CrossRef
  33. Liang WQ (2005) Biopharmaceutics and pharmacokinetics, 2nd edn. People鈥檚 Medical Publishing House, Beijing
  34. Yamaguchi H, Watanabe K, Hayashi M, Awazu S (1984) Effect of egg yolk phospholipids plasma elimination and tissue distribution of coenzyme Q10 administered in an emulsion to rats. J Pharm Pharmacol 36:768鈥?69 CrossRef
  35. Mizushima Y, Hamano T, Yokoyama K (1982) Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann Rheum Dis 41:263鈥?67 CrossRef
  36. Yanagikawa A (1982) Application of lipid particles as a novel carrier for various drugs. Jpn J Inflamm 2:251鈥?57
  37. Kawakami S, Yamashita F, Hashida M (2000) Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Adv Drug Deliver Rev 45:77鈥?8 CrossRef
  38. Takino T, Konishi K, Takakura Y, Hashida M (1994) Long circulating emulsion carrier system for highly lipophilic drugs. Biol Pharm Bull 17:121鈥?25 CrossRef
  39. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65鈥?1 CrossRef
  
• 作者单位：Zhenzhen Liu (1)
  Yukun Feng (1)
  Lunhui Zhang (1)
  Guofei Li (1)
  Lulu Geng (1)
  Yan Cui (1)
  Fei Teng (1)
  Xing Tang (1)
  Kaishun Bi (1)
  Xiaohui Chen (1)
  
  1. School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenhe District, Shenyang, 110016, China
  
• ISSN：1432-0843

文摘

Purpose Larotaxel is a new taxane compound with poor solubility. The aim of this study is to develop a new formulation to locate the poorly soluble drug and compare the pharmacokinetics and tissue distribution of larotaxel-loaded microsphere (LTX-LM) with the solution form larotaxel-solution (LTX-solution). Methods A sensitive and efficient UPLC-MS/MS method was developed and validated for determination of larotaxel in rat plasma and tissues and applied to assess the plasma protein binding, pharmacokinetics, and tissue distribution. Results Pharmacokinetic study indicated that larotaxel plasma disposition was triphasic, and LTX-LM group had markedly higher AUC, smaller clearance, and lower apparent volume of distribution than the LTX-solution group. The tissue distribution exhibited significant lower uptake of LTX-LM in lung, kidney, heart, muscle, and brain among all the tissues, indicating the advantage of LTX-LM over the solution form in reducing drug precipitation in vivo and toxicity in cardiovascular system and central nervous system. Conclusions These results suggest that lipid microsphere could be an effective parenteral carrier for LTX delivery in cancer treatment.